Filing summary
Source mismatch: The supplied filing is IKONICS Corporation’s Form 10-K for the fiscal year ended December 31, 2012, not a TeraWulf Inc. filing. It reports full-year results, not a standalone 2012 Q4 period.
Business context and reporting period
IKONICS develops and manufactures photochemical imaging products for screen printing and abrasive etching, and is developing industrial businesses in Micro-Machining and Digital Texturing (DTX). Its products are sold domestically and internationally through distributors and direct sales. No customer accounted for more than 10% of sales in 2012 or 2011.
Financial performance and liquidity
| Metric | 2012 | 2011 |
|---|---|---|
| Net sales | $17.31 million | $16.78 million |
| Gross profit / margin | $6.94 million / 40.1% | $6.71 million / 40.0% |
| Operating income | $1.03 million | $1.03 million |
| Net income | $694,000 | $698,000 |
| Basic and diluted EPS | $0.35 | $0.35 |
| Cash from operations | $1.18 million | $794,000 |
Cash and cash equivalents were $968,000 at year-end, with $1.44 million in short-term investments. The company had no line-of-credit borrowings; its $1.25 million secured line was due for renewal in October 2013. Total liabilities were $1.39 million, including $366,000 of deferred income taxes. The filing reports no off-balance-sheet arrangements.
Material changes versus 2011
- Sales rose 3.2% to a record, led by 6.6% domestic growth and 3.5% growth in IKONICS Imaging. Export sales declined slightly, primarily due to weaker Middle East sales.
- Gross margin edged up from 40.0% to 40.1%; operating income was nearly flat, while net income decreased slightly.
- Operating cash flow increased, but year-end cash declined by $899,000, principally reflecting the $2.00 million special dividend paid in December.
- Research and development expense increased to $630,000, or 3.6% of sales, from $512,000, or 3.1%.
Outlook, risks, and unusual items
Management planned approximately $725,000 of 2013 capital expenditures, mainly for Micro-Machining capacity and product testing and demonstrations, expected to be funded from operating cash flow. It intended to continue R&D, product development, and technology alliances. Management reported progress with aerospace customers and DTX, while noting that defense budget sequestration and delays to commercial aircraft programs could affect some aerospace sales. Other identified uncertainties include product acceptance, competition, raw-material costs, international expansion, economic conditions, and renewal of the credit line.
The company paid its first-ever cash dividend, a one-time $1.00 per share distribution totaling approximately $2.00 million. A $23,000 patent-application abandonment charge was recorded. A like-kind exchange of DTX printers resulted in a recognized $16,000 loss. The company changed to a self-funded medical plan in 2012 and recorded a $54,000 related liability at year-end. The independent auditor gave an unqualified opinion on the financial statements; the auditor did not attest to internal control effectiveness.
Important facts to verify
- Confirm the intended issuer and reporting period: this source identifies IKONICS Corporation and fiscal 2012, not TeraWulf Inc. or a Q4 filing.
- Verify the 2012 sales, earnings, cash-flow figures, and segment performance against the audited statements.
- Check the status and terms of the credit-line renewal expected after October 2013.
- Assess whether Micro-Machining aerospace demand and DTX adoption developed as management anticipated, and whether planned capital spending was completed.
- Consider the special dividend’s effect on cash and the company’s self-funded medical-claim estimates.